NCT01474135

AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure

A Double-masked, Randomized, Controlled Study Assessing the Safety and Ocular Hypotensive Efficacy of Two AR 12286/Travoprost Fixed-dose Combination Products Compared to Travatan® Z in Patients With Elevated Intraocular Pressure

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 93 (actual)
• Sponsor: Aerie Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 120 Years
• Healthy volunteers: Not accepted

Summary

This is a double-masked, randomized, controlled study assessing the safety and ocular hypotensive efficacy of two AR 12286/travoprost fixed-dose combination products compared to Travatan® Z in patients with elevated intraocular pressure

Conditions

• Glaucoma
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	0.25% AR-12286 / 0.004% travoprost
DRUG	0.5% AR-12286, 0.004% travoprost
DRUG	0.004% Travoprost

Timeline

• Start date: 2011-12-01
• Primary completion: 2012-04-01
• Completion: 2012-04-01
• First posted: 2011-11-18
• Last updated: 2016-09-23

Locations

9 sites across 1 country: United States